Celldex Therapeutics Q4 EPS $(0.83) Misses $(0.74) Estimate, Sales $4.13M Beat $840.00K Estimate
Author: Benzinga Newsdesk | February 26, 2024 08:05am
Celldex Therapeutics (NASDAQ:
CLDX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.74) by 12.16 percent. This is a 48.21 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $4.13 million which beat the analyst consensus estimate of $840.00 thousand by 391.67 percent. This is a 156.04 percent increase over sales of $1.61 million the same period last year.
Posted In: CLDX